Abstract
Oral metoclopramide (0.5 mg/kg/24 h) and a liquid alginic acid-antacid compound were administered to infants and children with gastroesophageal reflux (GER) in a double-blind randomized controlled trial. The effect of medication was measured with 24-h intraesophageal pH monitoring. Neither metoclopramide nor the alginic acid-antacid compound decreased the frequency or duration of gastroesophageal reflux.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adolescent
-
Alginates / therapeutic use*
-
Aluminum Hydroxide / therapeutic use*
-
Antacids / therapeutic use*
-
Bicarbonates / therapeutic use*
-
Child
-
Child, Preschool
-
Clinical Trials as Topic
-
Double-Blind Method
-
Drug Combinations / therapeutic use
-
Gastroesophageal Reflux / drug therapy*
-
Humans
-
Infant
-
Metoclopramide / therapeutic use*
-
Random Allocation
-
Silicic Acid / therapeutic use*
-
Silicon Dioxide / therapeutic use*
-
Sodium Bicarbonate*
Substances
-
Alginates
-
Antacids
-
Bicarbonates
-
Drug Combinations
-
Silicic Acid
-
Aluminum Hydroxide
-
alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination
-
Silicon Dioxide
-
Sodium Bicarbonate
-
Metoclopramide